These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
4. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures. Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M Front Immunol; 2019; 10():60. PubMed ID: 30761132 [TBL] [Abstract][Full Text] [Related]
5. Proteomics to study macrophage response to viral infection. Nyman TA; Matikainen S J Proteomics; 2018 May; 180():99-107. PubMed ID: 28647517 [TBL] [Abstract][Full Text] [Related]
10. Current Strategies of Antiviral Drug Discovery for COVID-19. Mei M; Tan X Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887 [TBL] [Abstract][Full Text] [Related]
11. Proteomics and integrative omic approaches for understanding host-pathogen interactions and infectious diseases. Jean Beltran PM; Federspiel JD; Sheng X; Cristea IM Mol Syst Biol; 2017 Mar; 13(3):922. PubMed ID: 28348067 [TBL] [Abstract][Full Text] [Related]
12. Mitigating the Impact of Antibacterial Drug Resistance through Host-Directed Therapies: Current Progress, Outlook, and Challenges. Chiang CY; Uzoma I; Moore RT; Gilbert M; Duplantier AJ; Panchal RG mBio; 2018 Jan; 9(1):. PubMed ID: 29382729 [TBL] [Abstract][Full Text] [Related]
14. Repurposing host-based therapeutics to control coronavirus and influenza virus. Li CC; Wang XJ; Wang HR Drug Discov Today; 2019 Mar; 24(3):726-736. PubMed ID: 30711575 [TBL] [Abstract][Full Text] [Related]
15. Proteomics of host-bacterial interactions: new insights from dual perspectives. Sukumaran A; Woroszchuk E; Ross T; Geddes-McAlister J Can J Microbiol; 2021 Mar; 67(3):213-225. PubMed ID: 33027598 [TBL] [Abstract][Full Text] [Related]
16. Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses. Park JG; Ávila-Pérez G; Nogales A; Blanco-Lobo P; de la Torre JC; Martínez-Sobrido L J Virol; 2020 Mar; 94(7):. PubMed ID: 31941776 [TBL] [Abstract][Full Text] [Related]
17. Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. Terrier O; Slama-Schwok A Adv Exp Med Biol; 2021; 1322():195-218. PubMed ID: 34258742 [TBL] [Abstract][Full Text] [Related]
18. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Zumla A; Rao M; Wallis RS; Kaufmann SH; Rustomjee R; Mwaba P; Vilaplana C; Yeboah-Manu D; Chakaya J; Ippolito G; Azhar E; Hoelscher M; Maeurer M; Lancet Infect Dis; 2016 Apr; 16(4):e47-63. PubMed ID: 27036359 [TBL] [Abstract][Full Text] [Related]
19. Host-directed drug targeting of factors hijacked by pathogens. Schwegmann A; Brombacher F Sci Signal; 2008 Jul; 1(29):re8. PubMed ID: 18648074 [TBL] [Abstract][Full Text] [Related]
20. Host directed therapies: COVID-19 and beyond. Tripathi D; Sodani M; Gupta PK; Kulkarni S Curr Res Pharmacol Drug Discov; 2021; 2():100058. PubMed ID: 34870156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]